AZ Taps Swedish Roots For Novel Protein Research
This article was originally published in Scrip
AstraZeneca PLC is tapping its Swedish roots with a groundbreaking collaboration aimed at exploring the potential of an emerging class of proteins using the newly mapped Secretome for new drug development.
You may also be interested in...
Novo Nordisk said it extended its global lead in the GLP-1 space during Q2 and outlined a strategy to dominate the growing market obesity market as its pipeline grows.
T-knife, a developer of T-cell receptors intended for T-cell therapy in solid tumor cancers, says the series A gives its development program three years of financial runway.
AstraZeneca will take Redx's RXC006 into clinical development, targeting fibrotic diseases, giving valuable credibility to the biotech’s Wnt pathway hypothesis.